The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Epcoritamab + R-CHOP overcomes high total metabolic tumor volume in high-risk large B-cell lymphoma
In this video, Juan Alderuccio, MD, Sylvester Comprehensive Cancer Center, Miami, FL, briefly comments on a study elucidating that epcoritamab combined with R-CHOP overcomes the poor risk feature of high total metabolic tumor volume in patients with high-risk large B-cell lymphoma (LBL). This presents a promising therapeutic approach for this patient population. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (Ai-generated)
This was a study that will also be presented during the meeting. And what we did is we evaluated metabolic tumor volume on screening PET scans. We know that a threshold of 210 milliliters has been associated with poor outcome in patients treated with R-CHOP. So we analyzed in this cohort of patients if that threshold was associated with poor outcome. And what we observed is that it seems that the combination of R-CHOP with epcoritamab is capable of overcoming the poor response features previously described with R-CHOP...
This was a study that will also be presented during the meeting. And what we did is we evaluated metabolic tumor volume on screening PET scans. We know that a threshold of 210 milliliters has been associated with poor outcome in patients treated with R-CHOP. So we analyzed in this cohort of patients if that threshold was associated with poor outcome. And what we observed is that it seems that the combination of R-CHOP with epcoritamab is capable of overcoming the poor response features previously described with R-CHOP.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Regeneron: Consultancy; AbbVie: Consultancy; Genmab: Research Funding; BeiGene: Research Funding; ADC Therapeutics: Consultancy, Research Funding; Genentech: Consultancy.
